CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
小分子化合物与 CAR-T 细胞治疗联合：增强肿瘤免疫治疗的新策略
英文原题：Combining Small-Molecular Compounds With CAR T-Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy.
查看英文原题
Combining Small-Molecular Compounds With CAR T-Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法已被证明是治疗血液系统恶性肿瘤的有效癌症免疫治疗策略，但耗竭、持久性有限和治疗相关毒性已被确定为实体瘤治疗的主要障碍。小分子化合物可以有效改善CAR-T 细胞疗法，例如防止耗竭、增强记忆形成和增强抗肿瘤活性。此外，基于四环素控制基因表达系统添加小分子开关是提高CAR-T 疗法安全性和减少其副作用的有效策略。尽管临床前和临床结果令人鼓舞，但在优化给药方案和管理药物相互作用方面仍存在挑战。本综述旨在总结联合方法的最新进展，并讨论其潜在获益的机制。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has been proved to be an effective cancer immunotherapy strategy against haematological malignancies, but exhaustion, limited persistence, and treatment-related toxicity have been identified as major roadblocks in solid tumour treatment. Small-molecular compounds could effectively improve CAR T-cell therapy, such as preventing exhaustion, enhancing memory formation, and enhancing the antitumor activity.
Additionally, adding small molecule switches based on tetracycline-controlled gene expression system is an effective strategy to improve the safety of CAR T therapy and reduce its side effects. Despite the encouraging preclinical and clinical results, challenges still remain in optimizing dosing regimens and managing drug interactions. This review aims to summarize recent advances in combined approach and to discuss the underlying mechanisms of its potential benefits.
论文信息
- 作者
- Yi R、Zhang Z、Yang Y、Zhu H
- 第一作者单位
- Department of Endocrinology, Tianyou Hospital, School of Medicine Wuhan University of Science and Technology Wuhan Hubei China.China
- 通讯作者单位
- National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education) Hubei University of Technology Wuhan Hubei China.China
- 文献类型
- 综述
- 期刊
- Cancer innovation2026 Apr
- 原文标识
- PubMed 41978748 · DOI 10.1002/cai2.70053
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →